Actualizado 01/03/2011 15:09
- Comunicado -

BARACLUDE(R) (entecavir) Approved by the European Commission for the Treatment of Chronic Hepatitis B in Adult Patients

2. Chu C-M and Liaw Y-F. Hepatitis B virus-related cirrhosis: Natural history and treatment. Seminars in Liver Disease 2006;26(2):142-152.

3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-S50.

4. Fattovich G, Pantalena M, Zagni I et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. 2002; 97: 2886-95.

5. Y. Liaw, et al. Efficacy and Safety of Entecavir versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation. Abstract and Poster 442. AASLD 2009.

6. World Helath Organization Web site. Fact sheet N- 204. http://www.who.int/mediacentre/factsheet.... Accessed 3 December 2010.

CONTACT: Contact: Media: Annie Simond, office: +33-1-58-83-65-66,annie.simond@bms.com

Contenido patrocinado